MedTrace Logo

Study to Investigate the Therapeutic Role of RNA Fragments in Platelet Production During Chemotherapy

NCT01163110 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2013-11-15

No results posted yet for this study

Summary

The purpose of this study is to measure the therapeutic potential of Escherichia coli (E. coli) and yeast ribosomal Ribonucleic acid (RNA) fragments to maintain the production of platelets in patients undergoing cytotoxic therapy for cancer.

Conditions

Interventions

DIETARY_SUPPLEMENT

Realbuild

Patient with chemotherapy induced thrombocytopenia takes RNA fragments orally to accelerate time to platelet recovery

Sponsors & Collaborators

  • Midwestern Regional Medical Center

    lead OTHER

Principal Investigators

  • Robert Levin, MD · Midwestern Regional Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01163110 on ClinicalTrials.gov